Can Drug Development Lifecycle Time be reduced?
Saturday, January 1st, 2011Can Drug Development Lifecycle Time be reduced?
Author: Hitesh Verma, General Manager, Life Sciences Practice at Intelligroup
“Time to Market” is a key mantra for a product or a service to start contributing to business growth and results. While a typical product starts its commercial operation anywhere between 1 and 3 years since the inception of the idea, a new pharmaceutical drug takes typically between 8 and 10 years, after the patent has been filed, to be approved for commercial marketing. With about 15% of the new chemical entities discovered making it to the commercial market in the “Time to Market” of 8 – 10 years, pharmaceutical companies constantly ask the question – can the Drug Development Lifecycle be reduced?
(more…)
Supply Chain Visibility In Pharmaceutical Industry
Monday, December 13th, 2010Author: Murali Sundararajan, Associate Director, Global Life Sciences Practice, Intelligroup
The Pharmaceutical Industry Supply Chain is highly complex in nature because of the involvement of a huge number of stakeholders in the chain. Because of this complexity, the Pharmaceutical Supply Chain is the biggest challenge for the supply chain experts, as well as the pharmaceutical professionals.
(more…)
Global Pharmaceutical IT Scenario and Landscape
Monday, December 13th, 2010Author: Murali Sundararajan, Associate Director, Global Life Sciences Practice, Intelligroup
The Global Pharmaceutical market is poised to grow at the rate of 4-7% and expected to reach $ 975 bn by 2013 (Pharmtech) . This growth is on a Global scenario and has a stronger presence in US market. The therapeutic segments which fuel this huge Pharmaceutical growth are Cardiovascular and Anti diabetic drugs. Anti Hypertensive drug segment is another important area of Therapeutics which will be predominant in next few years. This is due to change in Lifestyle and demographic conditions across the Globe.
(more…)
What’s IT got to do with it? Rethinking the IT/QA Equation in Life Sciences
Monday, November 8th, 2010Author: Sanjiv Shah, Head, Global Life Sciences Practice, Intelligroup
This past week a giant drug maker expanded the recall of their blockbuster cholesterol reduction medication bottles due to a musty odor in the bottles, bringing the total number of recalled bottles to more than 360,000. In the same week, another giant drug maker agreed to pay a $750 million fine for quality related violations at one of their plants that resulted in contaminated and mislabeled product entering the supply chain.
(more…)
INTERVIEW: SANJIV SHAH: ‘Fake drugs are a growing problem’
Sunday, October 10th, 2010Author: Sanjiv Shah, Head, Global Life Sciences Practice, Intelligroup
While counterfeit drugs have been around for decades, the internet’s growth and the popularity of Pfizer’s erectile dysfunction drug Viagra in the 1990s created the “perfect storm” to fuel this underground industry. Last year, nearly 1,700 incidents of counterfeit drugs were reported worldwide, triple the number in 2004, says the Pharmaceutical Security Institute (PSI), a group funded by drug makers. Estimates for the size of the counterfeit drug market range from $75 billion to $200 billion a year. Shockingly, 75% of fake drugs supplied globally have some origins in India, says Sanjiv Shah, head—global life sciences practice, Intelligroup, a leading provider of IT solutions to help drug companies counter the fake drug menace. In a recent interaction with BV Mahalakshmi, Shah lays emphasis on safety through traceability by means of epedigree, an electronic document being used by drug companies to protect consumers from fake medicines.Excerpts:
(more…)